Ninlaro ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
61	Autoimmune hemolytic anemia	1

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03783416 (ClinicalTrials.gov)	June 1, 2019	10/12/2018	SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis	Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial.	Relapsing Remitting Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: Ixazomib (NINLARO®) capsules / Matching placebo capsules	Queen Mary University of London	Takeda Pharmaceuticals International, Inc.	Not yet recruiting	18 Years	65 Years	All	72	Phase 1	United Kingdom

61. Autoimmune hemolytic anemia

---

Clinical trials : 146 /  Drugs : 131 - (DrugBank : 59) / Drug target genes : 28 - Drug target pathways : 158

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03965624 (ClinicalTrials.gov)	September 1, 2019	24/5/2019	Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia	A Prospective Open-label Trial to Assess the Efficacy and Safety of Ixazomib and Dexamethasone in Patients With Refractory Autoimmune Cytopenia	Immune Thrombocytopenia;Warm Autoimmune Hemolytic Anemia	Drug: Ninlaro	Assistance Publique - Hôpitaux de Paris	Takeda Pharmaceuticals International, Inc.	Withdrawn	18 Years	N/A	All	0	Phase 2	France